Trial Profile
Phase 2 Trial of Cabozantinib (XL184), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Cabozantinib (Primary)
- Indications Adenocarcinoma; Adrenal cancer; Adrenocortical carcinoma; Alveolar soft part sarcoma; Clear cell sarcoma; Ewing's sarcoma; Hepatoblastoma; Liver cancer; Nervous system neoplasms; Osteosarcoma; Renal cell carcinoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Wilms' tumour
- Focus Therapeutic Use
- 02 Nov 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 02 Jul 2021 Planned End Date changed from 30 Jun 2022 to 1 Jul 2022.
- 01 Jul 2021 Planned End Date changed from 30 Sep 2021 to 30 Jun 2022.